SCHEMBL230627

SCHEMBL230627

O=C(CBr)Nc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 5/20 0.62
HDAC1 Q13547 5/20 0.62
HDAC7 Q8WUI4 5/20 0.62
HDAC11 Q96DB2 5/20 0.62
HDAC8 Q9BY41 5/20 0.62
HDAC6 Q9UBN7 5/20 0.62
HDAC9 Q9UKV0 5/20 0.62
HDAC5 Q9UQL6 5/20 0.62
HDAC3 O15379 4/20 0.62
HDAC2 Q92769 4/20 0.62
HDAC10 Q969S8 4/20 0.62
EPHX2 P34913 2/20 0.61
KDM1A O60341 1/20 0.60
MAPT P10636 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
HTT P42858 1/20 0.57
TP53 P04637 1/20 0.56
EPHX1 P07099 1/20 0.56
TSHR P16473 1/20 0.56
CDK9 P50750 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopropane SCHEMBL27484508 0.94 EPHX2 (0.59) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL27783378 0.94 HDAC4 (0.57) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL20067991 0.92 MAPT (0.68) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL15267699 0.88 KMT2A (0.60) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL16197808 0.88 ALDH1A1 (0.68) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL3986889 0.85 EPHX2 (0.55) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL21765844 0.84 POLB (0.56) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1689206 0.83 EPHX2 (0.68) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4262750 0.83 RNF4 (0.71) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1573386 0.83 L3MBTL1 (0.63) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025074340-A1 A PROCESS FOR PREPARATION OF AMINOBIPHENYL COMPOUNDS AND INTERMEDIATES THEREOF UPL LIMITED (IN) 2025-04-10 WO claimed
CN-119306720-A Evodiamine derivative, rutaecarpine derivative, preparation method and application thereof 济宁市第一人民医院(济宁市医学科学研究院) 2025-01-14 CN claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
CN-101525304-B Preparation method for nitrogen-chloro acetanilide containing halogenated functional group UNIV WUHAN 2012-07-04 CN claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 WO claimed
CN-101525304-A Preparation method for nitrogen-chloro acetanilide containing halogenated functional group UNIV WUHAN 2009-09-09 CN claimed
EP-1885348-A2 ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE Amgen, Inc (US) 2008-02-13 EP claimed
WO-2006124753-A2 ANTIPYRETIC AGENTS AGAINST VR1-ANTAGONIST-INDUCED INCREASES IN BODY TEMPERATURE AMGEN INC. (US) 2006-11-23 WO claimed
US-5159082-A Catalytic coupling of an aromatic sulfinic acid with an aromatic halogen compound MITSUBISHI KASEI CORPORATION (JP) 1992-10-27 US claimed
EP-0405389-A1 Process for producing an aromatic compound Mitsubishi Chemical Corporation (JP) 1991-01-02 EP claimed
EP-0081384-B1 PROCESS FOR THE PREPARATION OF AROMATIC OR HETEROAROMATIC CARBOXYLATED COMPOUNDS Montedison S.p.A. (IT) 1986-04-02 EP claimed
EP-4061961-B1 METHOD FOR DOUBLE STRAND SEQUENCING OXFORD NANOPORE TECH PLC (GB) 2026-04-08 EP disclosed
US-20260072008-A1 METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE UNIV OXFORD INNOVATION LTD (GB) 2026-03-12 US disclosed
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-12 US disclosed
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE Oxford Nanopore Technolgies PLC (GB) 2026-03-05 US disclosed
US-3937730-A N-ALKOXY-N-CHLOROACETANILIDE CIBA-GEIGY CORPORATION (US) 1976-02-10 US disclosed
US-3898273-A Esterified bromoacetanilides AKZO AMERICA INC., A CORP. OF DE 1975-08-05 US disclosed
US-3898273-A Esterified bromoacetanilides AKZO AMERICA INC., A CORP. OF DE 1975-08-05 US disclosed
US-3892786-A Bromoacetanilides and their utility as biocides STAUFFER CHEMICAL CO 1975-07-01 US disclosed
US-3892786-A Bromoacetanilides and their utility as biocides STAUFFER CHEMICAL CO 1975-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260072008-A1 METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE MAX, NPPA, NUP210 HDAC4 4766/4885HDAC1 4868/4885HDAC7 4802/4885
US-20260063618-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, NPPA, NUP160 HDAC4 4844/4885HDAC1 4883/4885HDAC7 4842/4885
US-20260072009-A1 METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE NUP210, SLC9A2, SLC9A3 HDAC4 4868/4885HDAC1 4879/4885HDAC7 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.